Arm B of the phase II clinical trial TraMel-WT evaluated trametinib (competitive MEK1/2-inhibitor) combined with low-dose dabrafenib (to mitigate MEK-inhibitor-induced skin-toxicity) in 24 patients with pretreated BRAFV600/NRASQ61wild-type melanoma (NCT04059224). The gene discussed is MAP2K1; the disease is melanoma.